Raffaele Strippoli

Pubblicazioni

Titolo Pubblicato in Anno
Novel Aspects of the Immune Response Involved in the Peritoneal Damage in Chronic Kidney Disease Patients under Dialysis INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective CELL & BIOSCIENCE 2023
SYNCRIP Modulates the Epithelial-Mesenchymal Transition in Hepatocytes and HCC Cells INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2022
Exposure to b‐LED light while exerting antimicrobial activity on Gram‐negative and ‐positive bacteria promotes transient EMT‐like changes and growth arrest in keratinocytes INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2022
Restoration of WT1/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells CELL DEATH & DISEASE 2022
Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2022
Clinical Trials Involving Chemotherapy- Based Nanocarriers in Cancer Therapy: State of the Art and Future Directions Cancer Nanotechnology 2022
Ovarian cancer-driven mesothelial-to-mesenchymal transition is triggered by the endothelin-1/β-arr1 axis FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY 2021
Mechanisms of peritoneal fibrosis: focus on immune cells-peritoneal stroma interactions FRONTIERS IN IMMUNOLOGY 2021
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study THE LANCET. RHEUMATOLOGY 2021
Editorial: new approaches to tackle EMT and fibrosis: from epigenetics to nanotechnology FRONTIERS IN PHARMACOLOGY 2021
Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response JOURNAL OF HEPATOLOGY 2021
Autophagy and the lysosomal system in cancer CELLS 2021
Pleural mesothelial cells modulate the inflammatory/profibrotic response during SARS-CoV-2 infection FRONTIERS IN MOLECULAR BIOSCIENCES 2021
Molecular mechanisms and new therapeutic targets in epithelial to mesenchymal transition (EMT) and fibrosis FRONTIERS IN PHARMACOLOGY 2020
Novel quinoline compounds active in cancer cells through coupled DNA methyltransferase inhibition and degradation CANCERS 2020
Design of first-in-class dual EZH2/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells ACS MEDICINAL CHEMISTRY LETTERS 2020
Caveolin1 and YAP drive mechanically induced mesothelial to mesenchymal transition and fibrosis CELL DEATH & DISEASE 2020
Nanomaterials for Autophagy-Related miRNA-34a Delivery in Cancer Treatment FRONTIERS IN PHARMACOLOGY 2020
Design and functional validation of a mutant variant of the lncRNA HOTAIR to counteract Snail function in Epithelial-to-Mesenchymal Transition CANCER RESEARCH 2020

ERC

  • LS1_9
  • LS2_3
  • LS3
  • LS3_4
  • LS3_5
  • LS3_7
  • LS4_12
  • LS6
  • LS6_1
  • LS6_3

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

I have a background in innate immunity and in cellular/molecular biology. I am interested in molecular mechanisms controlling the induction/reversal of Epithelial to Mesenchymal Transition (EMT) and fibrosis. In particular, I focused my investigation in the role of both extracellular mediators and biomechanical/biophisical cues in the induction of cellular plasticity and signalling pathways implicated. I recently studied the interplay between Caveolin1, a plasma membrane mechanotransducer,  and YAP/TAZ, effectors of a main biomechanical pathway, in the induction of peritoneal fibrosis.

I am presently involved in research projects related to biomechanical regulation of EMT and to the control of EMT induction/reversal by epigenetic factors. Moreover, I am interested in the role of infections in the modulation of epithelial cell plasticity.

Keywords

cell signalling
Integrins
fibrosis mesothelial cells mechanotransduction YAP Caveolin1
Liver fibrosis
fibrosis
toll like receptors
Extracellular Signal-Regulated MAP Kinases
transforming growth factor beta (TGFβ)
epigenetics
HDAC inhibitors
biomechanics
pneumonia: Sars-Cov-2
Interleukin-6

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma